Copyright
©The Author(s) 2017.
World J Methodol. Mar 26, 2017; 7(1): 9-15
Published online Mar 26, 2017. doi: 10.5662/wjm.v7.i1.9
Published online Mar 26, 2017. doi: 10.5662/wjm.v7.i1.9
Disease | |||
Cardiovascular | Endocrine | Gastrointestinal | Inflammatory |
Acute coronary syndrome | Hyperparathyroidism | Chronic atrophic gastritis | Chronic bronchitis |
Arterial hypertension | Hyperthyroidism | Chronic hepatitis | Chronic obstructive pulmonary disease |
Cardiac insufficiency | Hypercortisolism | Inflammatory/irritable bowel syndrome | Giant cell arthritis |
Liver cirrhosis | Rheumatoid arthritis | ||
Pancreatitis | Systemic inflammatory response syndrome | ||
Drugs | |||
Corticoids | H2 receptor antagonist | Proton pump inhibitor | |
Status | |||
Exercise | Ingestion of a meal | Pregnancy | |
Factors having potential influence on sample | |||
Fibrin presence | Haemolysis | Imposing effect: Autoantibodies presence (RF-IgM, Avidine, Heterofile) | Late afternoon/night > morning |
Lipaemia | Plasma > serum | - |
- Citation: Gkolfinopoulos S, Tsapakidis K, Papadimitriou K, Papamichael D, Kountourakis P. Chromogranin A as a valid marker in oncology: Clinical application or false hopes? World J Methodol 2017; 7(1): 9-15
- URL: https://www.wjgnet.com/2222-0682/full/v7/i1/9.htm
- DOI: https://dx.doi.org/10.5662/wjm.v7.i1.9